Syphilis is a sexually transmitted infection (STI) that is passed through contact with a syphilis lesion (sore or chancre). Outbreaks of syphilis have been reported in every major Canadian urban centre, particularly among men who have sex with men (MSM). In recent years, the number of new cases has risen dramatically.
Symptoms of early syphilis vary considerably—from a painless chancre, a sore or a rash, to a fever, headache, problems with vision or more serious symptoms. Sexually active people should have blood tests for syphilis at least once a year. If caught early, syphilis can be treated effectively. If left untreated, syphilis can become a serious chronic disease.
In HIV-positive people, syphilis can cause damage faster and sometimes be harder to treat than in HIV-negative people. People infected with both syphilis and HIV can also transmit HIV more easily.
What is syphilis?
Syphilis is the name given to an infection caused by the bacteria Treponema pallidum, or T. pallidum. This disease can be spread when one person comes into contact with syphilis lesions (sores or chancres). For example, it can be passed through:
- wet kissing
- anal, oral or vaginal sexual contact
- sharing sex toys
- sharing equipment for injecting, smoking or snorting drugs
- pregnancy or birth from an infected mother to her child
The germs that cause syphilis (called treponemes or spirochetes) can cause lesions, sores or ulcers on the genitals, and inside the rectum and mouth. These sores can be an entry point for HIV and other STIs to get inside the body. Once inside the body, treponemes can enter the lymphatic system or the bloodstream. In a matter of hours or days, treponemes can quickly spread throughout the body and reach the brain.
Who is at risk for syphilis?
All people who are sexually active can be at risk for syphilis. People living with HIV are at greater risk of acquiring syphilis than HIV-negative people. Both men and women can get syphilis but more cases have been reported among men than women. Most of the new cases reported have been in men who have sex with men.
Many people with syphilis initially experience no symptoms (however, they can transmit syphilis and remain at risk for complications). Others experience a variety of symptoms that can range from mild to severe. If left untreated, syphilis can, cause serious illness.
In the early stages of syphilis, a lesion (sore) can appear on or inside the penis, vagina, rectum or mouth, usually two to three weeks after infection. In people co-infected with HIV, multiple lesions may appear. Because the lesions may be painless and may develop in hidden locations, early-stage syphilis in both men and women can go unnoticed.
Lymph nodes in the groin may become swollen, usually within a week of the syphilitic lesion appearing. Although the lesion can heal within four to six weeks, lymph nodes may remain swollen for several months.
However it is important to know that early-stage syphilis can have minimal or no symptoms and may go unnoticed by affected people. This is why frequent testing for syphilis is important for sexually active people. Troublingly, treponemes have been found in the spinal fluid of people with primary syphilis, regardless of whether they are HIV-positive or -negative. This means that the germs that cause syphilis have penetrated the central nervous system and can attack the brain. When this occurs, neurosyphilis can develop.
At this stage, generally two to 12 weeks after the lesion appears, symptoms of widespread infection can occur. Symptoms can vary considerably but the following are common:
- low-grade fever
- lack of energy
- sore throat
- lack of appetite
The rash can begin on the trunk but may also appear elsewhere, for example, on the palms of the hands and soles of the feet. If the rash affects a hairy area, temporary patchy hair loss can occur. For instance, thinning of the eyebrows, beard or parts of the head can be a feature of syphilitic rash.
Painless lesions, called mucous patches, can appear on the wet tissues of the genitals, mouth, throat and tonsils. These lesions are teeming with treponemes and are highly infectious.
In up to 40% of people with secondary syphilis, the brain and spinal cord (the central nervous system—CNS) can become infected, with or without symptoms. Some people may experience the following symptoms:
- ringing in the ears
- decreased ability to hear clearly
- difficulty seeing clearly
Late syphilis (tertiary syphilis)
Without treatment, secondary syphilis turns into late syphilis (also called latent or tertiary syphilis). This can develop from two to thirty years after infection. At this stage, no symptoms are present and the infection can only be detected with blood tests. However, the disease continues to cause damage.
At this stage of illness, any organ of the body may slowly become inflamed and affected by T. pallidum. Late syphilis can affect the nervous system (neurosyphilis, which can amplify HIV-related neurocognitive problems), the heart and blood vessels (cardiovascular syphilis), the liver (which can cause liver damage or hepatitis), the kidneys, eyes or just about any organ system.
If left untreated, late-stage syphilis can eventually lead to complications, including the following:
- difficulty falling asleep
- problems with vision
- peripheral neuropathy (damage to the nerves of the peripheral nervous system)
- problems getting and maintaining an erection
- changes in personality
- poor memory
- decreased capacity for insight and good judgment
- poor control of muscles
- damaged joints
In rare cases, untreated syphilis can be life-threatening.
Syphilis passed from mother to baby (congenital syphilis)
When a woman is infected with syphilis while pregnant, the disease can cause miscarriage, stillbirth or the death of a newborn. Most babies born with syphilis have no symptoms although some may have a rash. If the syphilis is not treated, babies can have developmental problems, seizures and other serious health issues.
Testing and diagnosis (screening)
Syphilis is commonly diagnosed using blood tests that detect antibodies to proteins unrelated to T. pallidum but which occur in cases of syphilis. Blood tests commonly used to help diagnose syphilis include the following:
- VDRL (venereal disease research laboratory)
- RPR (rapid plasma reagin)
In people with primary syphilis or latent syphilis, these indirect tests do not always work. If syphilis is suspected but the test produces a negative result, the Public Health Agency of Canada (PHAC) recommends that doctors repeat the test several weeks later and also consider using tests that look specifically for antibodies to T. pallidum. These tests include:
- treponemal enzyme immunoassay (EIA)
Some provincial laboratories reverse the order of these tests and first use tests that assess the presence of antibodies to T. pallidum. For more information about which tests are available in your region and the order of tests used, contact your doctor or local laboratory.
In some cases, syphilis can also be diagnosed by swabbing an infectious chancre and examining the sample under a microscope.
Screening is recommended for sex partners who may have syphilis, men who have sex with men, injection drug users, sex workers and people who have had sex with people from endemic countries. Because untreated syphilis in a pregnant woman can infect and potentially harm her developing fetus or newborn, every pregnant woman should get tested.
Researchers in the Netherlands have suggested that routine assessment of blood for syphilis may be useful in HIV-positive MSM because syphilis can, at least initially, be symptom-free.
Notification of partners
Syphilis is a reportable infection. This means that when an infection is confirmed by a clinic, doctor, or laboratory it must be reported to public health authorities. When someone has a confirmed syphilis diagnosis, they will be asked by the healthcare provider or public health nurse to contact or provide contact information for all their sexual partners during their trace-back period (the time period before symptoms started or if asymptomatic, the time prior to specimen collection) based on their stage of syphilis.
The trace-back periods for syphilis stages are:
- primary syphilis – three months
- secondary syphilis – six months
- early latent – one year
- late latent/tertiary – depending on the estimated time of original infection, long-term partners (spouses) and children should be screened.
If no partners in the recommended trace-back period test positive for syphilis, the next most recent partner outside of the trace-back period should be notified.
If the client chooses not to contact their sexual partners, the healthcare provider or public health nurse will attempt to contact the partners and encourage them to be tested and treated for syphilis. The name of the original client is not given to the sexual partners when they are contacted in an attempt to retain their anonymity. PHAC recommends that all notified partners be treated without waiting for test results.
An antibiotic called benzathine penicillin G is considered the gold standard of anti-syphilis therapy. If syphilis is diagnosed within a year of infection, it can usually be treated with a single injection of this type of penicillin (a single dose of 2.4 million units injected into muscle, usually in the buttocks). It is important to note that this dose is inadequate for people with neurosyphilis.
People who have had syphilis for more than a year need to take higher doses of the medication for longer. In cases of neurosyphilis, Canadian guidelines recommend an intravenous formulation of penicillin, such as penicillin G. When used to treat neurosyphilis, this intravenous formulation of penicillin is given in a dose of several million units every four hours for between 10 and 14 days. Some doctors may decide to use a longer period of treatment depending on the severity of symptoms.
Antibiotics such as doxycycline impair the growth of treponemes and are sometimes used in patients who are allergic to penicillin. Bear in mind that unlike penicillin, doxycycline does not kill treponemes and may be less effective in people with severely weakened immune systems. For people who are allergic to penicillin and for pregnant women with syphilis, some experts prefer to desensitize their patients to penicillin. This involves giving people tiny but gradually increasing amounts of penicillin under close medical supervision, until they are able to tolerate a complete dose.
The antibiotic azithromycin (Zithromax) has also been used to treat syphilis; however, cases of syphilis resistant to azithromycin have been reported in Canada, the United States and other countries, particularly among MSM. PHAC does not recommend the use of this antibiotic for the routine treatment of syphilis. Similarly, the antibiotic ceftriaxone is not recommended for routine treatment of syphilis in Canada.
What about HIV infection?
The treatment of syphilis in people co-infected with HIV is controversial. Some physicians favour using the same therapy that would be used in HIV-negative people—a single intramuscular injection of benzathine penicillin. Others opt for more rigorous therapy for HIV-positive people, due to the following factors:
- There is a high risk of treponemes invading the brain, even in primary syphilis, so a single injection of penicillin may be inadequate.
- HIV-positive people are at high risk for neurological problems and neurosyphilis may increase this risk.
- HIV infection weakens the immune system and possibly its ability to control syphilis.
- Syphilis is a relatively common STI among sexually active MSM.
Such considerations have prompted some physicians to use benzathine penicillin, injected intramuscularly, once a week for three consecutive weeks, as treatment in HIV-positive people for primary or secondary syphilis.
Alternatively, physicians may opt for the antibiotic doxycycline taken orally twice daily for two to four consecutive weeks. Although effective in early-stage syphilis, doxycycline has not been tested for late-stage syphilis. Some syphilis experts recommend desensitization to penicillin in patients with an allergy to penicillin, followed by penicillin treatment.
For neurosyphilis, regardless of a person’s HIV infection status, PHAC recommends therapy with penicillin for 10 to 14 days.
PHAC has excellent guidelines (Canadian Guidelines on Sexually Transmitted Infections) for the management of patients with syphilis, including a penicillin desensitization plan.
Sex after syphilis
It takes time for treponeme levels to decrease and for your body to recover from syphilis. Even though you may feel better after syphilis treatment, there may still be treponemes lurking in your body. Your doctor will order blood tests to let you know when your body has recovered and when it is safe for you to resume sexual activity.
PHAC recommends re-screening for syphilis three, six and 12 months after treatment for those not co-infected with HIV. PHAC outlines specific treatment plans based on the patient and type of syphilis.
To prevent the transmission of syphilis, you can:
Practice safer sex.
- Use latex or polyisoprene condoms and/or dental dams for all sexual activities, including oral sex. (This does not eliminate the chance of transmission because a syphilis lesion may be in an area not covered by a condom or dental dam, but consistent use reduces the risk.)
- Talk to your sex partners about their history of STIs.
- If you or your partner notices any unusual discharge, a sore or a rash, especially around the groin, avoid having sex and see your doctor as soon as possible.
Get tested and treated.
- Get tested regularly for syphilis. If you are a pregnant woman, get tested early on in your pregnancy.
- If you test positive, treat the infection as soon as possible and notify your sex partner(s), so they can get tested too. It is important that the people you have had sex with know that they may have been exposed to syphilis; however, doing this is not always easy. So ask your doctor or nurse for a referral to your local public health department, which can discreetly inform your sexual partner(s) of their need for syphilis testing.
If you use drugs, avoid sharing drug equipment.
For more information about syphilis and HIV, see “The story of syphilis” in The Positive Side magazine (Spring/Summer 2004).
Woolston S, Cohen SE, Fanfair RN, et al. A cluster of ocular syphilis cases— Seattle, Washington, and San Francisco, California, 2014-2015. Morbidity and Mortality Weekly Report. 2015 Oct 16;64(40):1150-1.
Lukehart SA, Hook EW 3rd, Baker-Zander SA et al. Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Annals of Internal Medicine. 1988 Dec 1;109(11):855–62.
Tramont EC. Treponema pallidum (syphilis). In: Mandell GL, Bennett JE and Dolin R, editors. Principles and Practice of Infectious Diseases. Sixth ed. Philadelphia: Elsevier; 2005. 2362–79.
Lukehart SA. Syphilis. In: Fauci AS, Braunwald E, Kasper DL, editors. Harrison’s Principles of Internal Medicine. 17th ed. McGraw-Hill Companies, Inc.; 2008. 956–62.
Dowell ME, Ross PG, Musher DM et al. Response of latent syphilis or neurosyphilis to ceftriaxone therapy in persons infected with human immunodeficiency virus. American Journal of Medicine. 1992 Nov;93(5):481–8.
Gordon SM, Eaton ME, George R et al. The response of symptomatic neurosyphilis to high-dose intravenous penicillin G in patients with human immunodeficiency virus infection. New England Journal of Medicine. 1994 Dec 1;331(22):1469–73.
Marra CM, Maxwell CL, Smith SL et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. Journal of Infectious Diseases. 2004 Feb 1;189(3):369–76.
Thorne C, Malyuta R, Semenenko I et al. Mother-to-child transmission risk is increased among HIV-infected pregnant women in Ukraine with serological test results positive for syphilis. Clinical Infectious Diseases. 2008 Oct 15;47(8):1114–5.
Leslie DE, Higgins N, Fairley CK. Dangerous liaisons—syphilis and HIV in Victoria. Medical Journal of Australia. 2008 Jun 2;188(11):676–7.
Buchacz K, Klausner JD, Kerndt PR et al. HIV incidence among men diagnosed with early syphilis in Atlanta, San Francisco, and Los Angeles, 2004 to 2005. Journal of Acquired Immune Deficiency Syndromes. 2008 Feb 1;47(2):234–40.
Peeling RW, Hook EW 3rd. The pathogenesis of syphilis: the Great Mimicker, revisited. Journal of Pathology. 2006 Jan;208(2):224–32.
Lukehart SA, Godornes C, Molini BJ et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. New England Journal of Medicine. 2004 Jul 8;351(2):154–8.
Marra CM, Colina AP, Godornes C et al. Antibiotic selection may contribute to increases in macrolide-resistant Treponema pallidum. Journal of Infectious Diseases. 2006 Dec 15;194(12):1771–3.
Morshed MG, Jones HD. Treponema pallidum macrolide resistance in BC. Canadian Medical Association Journal. 2006 Jan 31;174(3):349.
de Almeida SM, Bhatt A, Riggs PK et al. Cerebrospinal fluid human immunodeficiency virus viral load in patients with neurosyphilis. Journal of Neurovirology. 2010 Feb;16(1):6-12.
Wallace MR, Heaton RK, McCutchan JA et al. Neurocognitive impairment in human immunodeficiency virus infection is correlated with sexually transmitted disease history. Sexually Transmitted Diseases. 1997 Aug;24(7):398-401.
Muldoon EG, Hogan A, Kilmartin D et al. Syphilis consequences and implications in delayed diagnosis: five cases of secondary syphilis presenting with ocular symptoms. Sexually Transmitted Infections. 2010 Dec;86(7):512-3.
Bani-Hani S, Patel V, Larsen CP et al. Renal disease in AIDS: it is not always HIVAN. Clinical and Experimental Nephrology. 2010 Jun;14(3):263-7.
Towns JM, Leslie DE, Denham I, et al. Painful and multiple anogenital lesions are common in men with Treponema pallidum PCR-positive primary syphilis without herpes simplex virus coinfection: a cross-sectional clinic-based study. Sexually Transmitted Infections. 2015; in press.
Roberts WC, Barbin CM, Weissenborn MR, et al. Syphilis as a cause of thoracic aortic aneurysm. American Journal of Cardiology. 2015 Oct 15;116(8):1298-303.
Lee SY, Cheng V, Rodger D, et al. Clinical and laboratory characteristics of ocular syphilis: a new face in the era of HIV co-infection. Journal of Ophthalmic Inflammation and Infection. 2015 Dec;5(1):56.
Author(s): Hosein SR